NEW YORK (GenomeWeb News) - Stratagene said today that it has acquired an exclusive licensing option to a family of patents related to bladder cancer owned by Denmark’s AROS Applied Biotechnology.
 
Under the agreement, Stratagene has the right to evaluate and exclusively license the rights to certain gene groups that have predictive capabilities for bladder cancer.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

In Nature this week: a Danish reference genome, and more.